These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

159 related items for PubMed ID: 12063552

  • 1. Antisense oligonucleotide targeted to RIalpha subunit of cAMP-dependent protein kinase (GEM231) enhances therapeutic effectiveness of cancer chemotherapeutic agent irinotecan in nude mice bearing human cancer xenografts: in vivo synergistic activity, pharmacokinetics and host toxicity.
    Wang H, Hang J, Shi Z, Li M, Yu D, Kandimalla ER, Agrawal S, Zhang R.
    Int J Oncol; 2002 Jul; 21(1):73-80. PubMed ID: 12063552
    [Abstract] [Full Text] [Related]

  • 2. GEM 231, a second-generation antisense agent complementary to protein kinase A RIalpha subunit, potentiates antitumor activity of irinotecan in human colon, pancreas, prostate and lung cancer xenografts.
    Agrawal S, Kandimalla ER, Yu D, Ball R, Lombardi G, Lucas T, Dexter DL, Hollister BA, Chen SF.
    Int J Oncol; 2002 Jul; 21(1):65-72. PubMed ID: 12063551
    [Abstract] [Full Text] [Related]

  • 3. Antisense anti-MDM2 mixed-backbone oligonucleotides enhance therapeutic efficacy of topoisomerase I inhibitor irinotecan in nude mice bearing human cancer xenografts: In vivo activity and mechanisms.
    Wang H, Wang S, Nan L, Yu D, Agrawal S, Zhang R.
    Int J Oncol; 2002 Apr; 20(4):745-52. PubMed ID: 11894120
    [Abstract] [Full Text] [Related]

  • 4. Antitumor activity and pharmacokinetics of a mixed-backbone antisense oligonucleotide targeted to the RIalpha subunit of protein kinase A after oral administration.
    Wang H, Cai Q, Zeng X, Yu D, Agrawal S, Zhang R.
    Proc Natl Acad Sci U S A; 1999 Nov 23; 96(24):13989-94. PubMed ID: 10570186
    [Abstract] [Full Text] [Related]

  • 5. Antisense protein kinase A RIalpha acts synergistically with hydroxycamptothecin to inhibit growth and induce apoptosis in human cancer cells: molecular basis for combinatorial therapy.
    Cho YS, Cho-Chung YS.
    Clin Cancer Res; 2003 Mar 23; 9(3):1171-8. PubMed ID: 12631623
    [Abstract] [Full Text] [Related]

  • 6. CpG immunomer DNA enhances antisense protein kinase A RIalpha inhibition of multidrug-resistant colon carcinoma growth in nude mice: molecular basis for combinatorial therapy.
    Nesterova MV, Johnson NR, Stewart T, Abrams S, Cho-Chung YS.
    Clin Cancer Res; 2005 Aug 15; 11(16):5950-5. PubMed ID: 16115938
    [Abstract] [Full Text] [Related]

  • 7. Experimental therapy of human prostate cancer by inhibiting MDM2 expression with novel mixed-backbone antisense oligonucleotides: in vitro and in vivo activities and mechanisms.
    Wang H, Yu D, Agrawal S, Zhang R.
    Prostate; 2003 Feb 15; 54(3):194-205. PubMed ID: 12518324
    [Abstract] [Full Text] [Related]

  • 8. Antisense anti-MDM2 oligonucleotides as a novel therapeutic approach to human breast cancer: in vitro and in vivo activities and mechanisms.
    Wang H, Nan L, Yu D, Agrawal S, Zhang R.
    Clin Cancer Res; 2001 Nov 15; 7(11):3613-24. PubMed ID: 11705884
    [Abstract] [Full Text] [Related]

  • 9. A safety and pharmacokinetic study of a mixed-backbone oligonucleotide (GEM231) targeting the type I protein kinase A by two-hour infusions in patients with refractory solid tumors.
    Chen HX, Marshall JL, Ness E, Martin RR, Dvorchik B, Rizvi N, Marquis J, McKinlay M, Dahut W, Hawkins MJ.
    Clin Cancer Res; 2000 Apr 15; 6(4):1259-66. PubMed ID: 10778949
    [Abstract] [Full Text] [Related]

  • 10. Combined blockade of protein kinase A and bcl-2 by antisense strategy induces apoptosis and inhibits tumor growth and angiogenesis.
    Tortora G, Caputo R, Damiano V, Bianco R, Fontanini G, Cuccato S, De Placido S, Bianco AR, Ciardiello F.
    Clin Cancer Res; 2001 Aug 15; 7(8):2537-44. PubMed ID: 11489837
    [Abstract] [Full Text] [Related]

  • 11. Anti-tumor efficacy of a novel antisense anti-MDM2 mixed-backbone oligonucleotide in human colon cancer models: p53-dependent and p53-independent mechanisms.
    Wang H, Nan L, Yu D, Lindsey JR, Agrawal S, Zhang R.
    Mol Med; 2002 Apr 15; 8(4):185-99. PubMed ID: 12149568
    [Abstract] [Full Text] [Related]

  • 12. Potentiation of antitumor activity of irinotecan by chemically modified oligonucleotides.
    Agrawal S, Kandimalla ER, Yu D, Hollister BA, Chen SF, Dexter DL, Alford TL, Hill B, Bailey KS, Bono CP, Knoerzer DL, Morton PA.
    Int J Oncol; 2001 May 15; 18(5):1061-9. PubMed ID: 11295057
    [Abstract] [Full Text] [Related]

  • 13. A phase I safety and dose escalation trial of docetaxel combined with GEM231, a second generation antisense oligonucleotide targeting protein kinase A R1alpha in patients with advanced solid cancers.
    Goel S, Desai K, Macapinlac M, Wadler S, Goldberg G, Fields A, Einstein M, Volterra F, Wong B, Martin R, Mani S.
    Invest New Drugs; 2006 Mar 15; 24(2):125-34. PubMed ID: 16683205
    [Abstract] [Full Text] [Related]

  • 14. The histone deacetylase inhibitor PXD101 increases the efficacy of irinotecan in in vitro and in vivo colon cancer models.
    Na YS, Jung KA, Kim SM, Hong YS, Ryu MH, Jang SJ, Moon DH, Cho DH, Kim JC, Lee JS, Kim TW.
    Cancer Chemother Pharmacol; 2011 Aug 15; 68(2):389-98. PubMed ID: 21046105
    [Abstract] [Full Text] [Related]

  • 15. Oligonucleotide sequence-specific inhibition of gene expression, tumor growth inhibition, and modulation of cAMP signaling by an RNA-DNA hybrid antisense targeted to protein kinase A RIalpha subunit.
    Nesterova M, Cho-Chung YS.
    Antisense Nucleic Acid Drug Dev; 2000 Dec 15; 10(6):423-33. PubMed ID: 11198926
    [Abstract] [Full Text] [Related]

  • 16. Antitumor activity of combined treatment of human cancer cells with ionizing radiation and anti-epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase A antisense oligonucleotide.
    Bianco C, Bianco R, Tortora G, Damiano V, Guerrieri P, Montemaggi P, Mendelsohn J, De Placido S, Bianco AR, Ciardiello F.
    Clin Cancer Res; 2000 Nov 15; 6(11):4343-50. PubMed ID: 11106252
    [Abstract] [Full Text] [Related]

  • 17. Oral antisense that targets protein kinase A cooperates with taxol and inhibits tumor growth, angiogenesis, and growth factor production.
    Tortora G, Bianco R, Damiano V, Fontanini G, De Placido S, Bianco AR, Ciardiello F.
    Clin Cancer Res; 2000 Jun 15; 6(6):2506-12. PubMed ID: 10873106
    [Abstract] [Full Text] [Related]

  • 18. Compensatory stabilization of RIIbeta protein, cell cycle deregulation, and growth arrest in colon and prostate carcinoma cells by antisense-directed down-regulation of protein kinase A RIalpha protein.
    Nesterova M, Noguchi K, Park YG, Lee YN, Cho-Chung YS.
    Clin Cancer Res; 2000 Sep 15; 6(9):3434-41. PubMed ID: 10999726
    [Abstract] [Full Text] [Related]

  • 19. Enhanced therapeutic effects of doxorubicin and paclitaxel in combination with liposome-entrapped ends-modified raf antisense oligonucleotide against human prostate, lung and breast tumor models.
    Mewani RR, Tang W, Rahman A, Dritschilo A, Ahmad I, Kasid UN, Gokhale PC.
    Int J Oncol; 2004 May 15; 24(5):1181-8. PubMed ID: 15067340
    [Abstract] [Full Text] [Related]

  • 20. Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect.
    Tortora G, Caputo R, Damiano V, Melisi D, Bianco R, Fontanini G, Veneziani BM, De Placido S, Bianco AR, Ciardiello F.
    Clin Cancer Res; 2003 Apr 15; 9(4):1566-72. PubMed ID: 12684433
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.